Nyxoah's Stock Rebounds 12% in Session After a 52% Annual Decline
The stock of the Belgian medtech company specializing in sleep apnea treatment has shown a significant rebound this Tuesday, trading at 2.70 euros during the session. This surge comes amidst a prolonged downturn, with the stock having lost over 52% over the past year and 41% in the last three months.
At midday, Nyxoah is trading at 2.70 euros, up 12.73% from the previous close of 2.40 euros. However, this movement is part of a negative underlying dynamic: over the past seven days, the stock has still lost 11.18%. The 50-day moving average, at 3.73 euros, and the 200-day average, at 4.87 euros, remain well above the current price, confirming the predominance of the downward trend. The RSI, at 21, indicates a marked oversold zone, which could mechanically explain this temporary rebound after several sessions of decline. The stock is trading in the lower part of the Bollinger Bands, close to the lower limit set at 2.35 euros, while the upper limit is at 4.04 euros. The nearest technical support, at 2.66 euros, has been tested and seems to currently hold back the selling pressure. The major resistance, identified at 4.00 euros, remains far from the current price, illustrating the significant distance the stock must cover to return to levels more in line with its valuation at the end of 2025.
Upcoming Financial Calendar and Market Context
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The next key date in the company's financial calendar is the publication of the first quarter 2026 results, scheduled for May 12. This event could be a crucial catalyst for the stock's trajectory, in a context where monthly volatility stands at 18.19%. This will be followed by the general assembly scheduled for June 10, and then the semi-annual results on August 5. The negative beta of -0.28 indicates a generally decoupled evolution from the major European indices, which are showing a positive trend this Tuesday: the CAC 40 is up 0.60% in session at 8,285.33 points, while the DAX has advanced 0.94% to 23,964.87 points. The S&P 500 closed up 1.02% at 6,886.24 points. Nyxoah's progress today thus does not seem directly linked to the direction of the markets but rather to a dynamic specific to the stock, after a prolonged period of decline that has brought the price to floor levels.
Related
SectorDispositifs médicaux et optique›Dispositifs médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: T3 2026
Key reported figures
Revenue: 9,2 millions d'euros
Quarterly revenue: 9,2 millions d'euros
Revenue growth: 366,5 %
Guidance from the release
Bien que nous soyons déçus d'ajuster nos prévisions de chiffre d'affaires
Risks mentioned
Ajustement à la baisse des prévisions de chiffre d'affaires (de 36-40 M€ à 33-35 M€)
Trajectoire de croissance inférieure aux attentes pour l'exercice 2026
Dépendance à la ramp-up des États-Unis reflétant les cycles historiques d'une nouvelle technologie
Opportunities identified
Supplément PMA soumis à la FDA pour étendre l'indication américaine aux patients atteints de collapsus concentrique complet
Croissance séquentielle de 29 % du chiffre d'affaires aux États-Unis au T3 2026
Expansion du nombre de chirurgiens formés (342 cumulés) et comptes activés (233 à fort volume) aux États-Unis
Outlook / guidance
Expected revenue: 34 millions d'euros
Management commentary: The Company now expects global net revenue for the full year 2026 to be in the range of €33 million to €35 million, compared to €36 million to €40 million previously.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
